Séverine Crettol Wavre

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


65 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
Sous presse
 
Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients.
Ansermot N., Vathanarasa H., Ranjbar S., Gholam M., Crettol S., Vandenberghe F., Gamma F., Plessen K.J., von Gunten A., Conus P. et al. Therapeutic drug monitoring. Peer-reviewed.
[DOI][Pmid][serval:BIB_4F77D255DA0E]
2024
A population pharmacokinetic model for sertraline in women during the perinatal period-A contribution from the ConcePTION project.
Monfort A., Cardoso E., Eap C.B., Ansermot N., Crettol S., Fischer Fumeaux C.J., Graz M.B., Harari M.M., Weisskopf E., Gandia P. et al., 2024/11. British journal of clinical pharmacology, 90 (11) pp. 2849-2860. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_09F8B14E5C96]
 
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics.
Hart X.M., Gründer G., Ansermot N., Conca A., Corruble E., Crettol S., Cumming P., Frajerman A., Hefner G., Howes O. et al., 2024/11. The world journal of biological psychiatry, 25 (9) pp. 451-536. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_770E26319158]
 
Self-reported caffeine consumption miss-matched consumption measured by plasma levels of caffeine and its metabolites: results from two population-based studies.
Laaboub N., Ranjbar S., Strippoli M.F., Marques-Vidal P., Estoppey-Younes S., Ponte B., Pruijm M., Vogt B., Ansermot N., Crettol S. et al., 2024/08. European journal of nutrition, 63 (5) pp. 1555-1564. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D000B2F7D371]
2023
 
Prescription d’antipsychotiques chez les adultes : à quoi faut-il être attentif ? [Antipsychotic prescribing in adults : what to watch out for ?]
Grandjean C., Vandenberghe F., Dubath C., Sibailly G., Ansermot N., Crettol Wavre S., Eap C.B., 2023/09/20. Revue medicale suisse, 19 (842) pp. 1707-1712. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A5F7D63D1926]
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis.
Sjaarda J., Delacrétaz A., Dubath C., Laaboub N., Piras M., Grosu C., Vandenberghe F., Crettol S., Ansermot N., Gamma F. et al., 2023/06. Molecular psychiatry, 28 (6) pp. 2320-2327. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC34831410AA]
2022
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples.
Perry B.I., Vandenberghe F., Garrido-Torres N., Osimo E.F., Piras M., Vazquez-Bourgon J., Upthegrove R., Grosu C., De La Foz V.O., Jones P.B. et al., 2022/11. The Lancet regional health. Europe, 22 p. 100493. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A56B7AE8F057]
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.
Laaboub N., Dubath C., Ranjbar S., Sibailly G., Grosu C., Piras M., Délessert D., Richard-Lepouriel H., Ansermot N., Crettol S. et al., 2022/05/17. BMC psychiatry, 22 (1) p. 342. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E9824076089]
Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.
Schoretsanitis G., Dubath C., Grosu C., Piras M., Laaboub N., Ranjbar S., Ansermot N., Crettol S., Vandenberghe F., Gamma F. et al., 2022/04. Basic & clinical pharmacology & toxicology, 130 (4) pp. 531-541. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_995572119F81]
Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity.
Guinchat V., Ansermot N., Ing Lorenzini K., Politis D., Daali Y., Eap C.B., Crettol S., 2022. Frontiers in psychiatry, 13 p. 910684. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8AD25DFBCE50]
2021
Gabapentinoïdes : mésusages et addictions [Gabapentinoids : misuses and addictions]
Grandjean C., Crettol Wavre S., Khazaal Y., Sanchis Zozaya J., Ansermot N., Vandenberghe F., Sibailly G., Eap C.B., 2021/12/15. Revue medicale suisse, 17 (763) pp. 2206-2208. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_CADF3E9C3F84]
Recommandations de prise en charge des mésusages et addictions aux benzodiazepines [Recommendations for management of misuses and addictions to benzodiazepines]
Grandjean C., Crettol Wavre S., Khazaal Y., Sanchis Zozaya J., Ansermot N., Vandenberghe F., Sibailly G., Eap C.B., 2021/10/13. Revue medicale suisse, 17 (754) pp. 1754-1759. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5EEA6C9D3688]
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
Eap C.B., Gründer G., Baumann P., Ansermot N., Conca A., Corruble E., Crettol S., Dahl M.L., de Leon J., Greiner C. et al., 2021/10. The world journal of biological psychiatry, 22 (8) pp. 561-628. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6FD14CC75A02]
Traitement de l’insomnie, par quoi commencer ? [Treatment of insomnia, with what to start ?]
Grandjean C., Crettol Wavre S., Ansermot N., Vandenberghe F., Sibailly G., Eap C.B., 2021/05/05. Revue medicale suisse, 17 (737) pp. 890-897. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_44F7FFE9FAFC]
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort.
Laaboub N., Gholam M., Sibailly G., Sjaarda J., Delacrétaz A., Dubath C., Grosu C., Piras M., Ansermot N., Crettol S. et al., 2021. Frontiers in psychiatry, 12 p. 756403. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C84BB0F598EF]
2020
Agitation aiguë chez l’adulte : proposition d’un algorithme de traitement psychopharmacologique [Rapid tranquilisation in adults : algorithm proposed for psychopharmacological treatment]
Crettol Wavre S., Ansermot N., Sibailly G., Vandenberghe F., Grandjean C., Teixeira Robalo B., Fassassi Gallo S., Thonney J., Solida-Tozzi A., Conus P. et al., 2020/09/23. Revue medicale suisse, 16 (707) pp. 1751-1755. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7B77DD272619]
2019
 
Genetic and clinic predictors of new onset diabetes mellitus after transplantation.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Mueller N.J., Binet I., Van Delden C., Steiger J., Mohacsi P. et al., 2019/02. The pharmacogenomics journal, 19 (1) pp. 53-64. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BA7F0AAB7E2E]
 
Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.
Ghassabian S., Gillani T.B., Rawling T., Crettol S., Nair P.C., Murray M., 2019/01/09. The AAPS journal, 21 (2) p. 15. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_49F3FF816FB5]
Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients.
Quteineh L., Wójtowicz A., Bochud P.Y., Crettol S., Vandenberghe F., Venetz J.P., Manuel O., Golshayan D., Lehmann R., Mueller N.J. et al., 2019/01. American journal of transplantation, 19 (1) pp. 238-246. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6D920C4CDD77]
2018
Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances
Delacrétaz Aurélie, Vandenberghe Frederik, Glatard Anaïs, Levier Axel, Dubath Céline, Ansermot Nicolas, Crettol Séverine, Gholam-Rezaee Mehdi, Guessous Idris, Bochud Murielle et al., 2018/11/09. Frontiers in Psychiatry, 9.
[URN][DOI][WoS][Pmid][serval:BIB_EFD90D5BB70B]
2017
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.
Quteineh L., Bochud P.Y., Golshayan D., Crettol S., Venetz J.P., Manuel O., Kutalik Z., Treyer A., Lehmann R., Mueller N.J. et al., 2017/01. The pharmacogenomics journal, 17 (1) pp. 69-75. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_342B86B6E988]
2016
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C., Crettol S., Guidi M., Eap C.B., 2016/12. Clinical pharmacokinetics, 55 (12) pp. 1521-1533. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_038FD2A79BD0]
Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.
Vandenberghe F., Saigí-Morgui N., Delacrétaz A., Quteineh L., Crettol S., Ansermot N., Gholam-Rezaee M., von Gunten A., Conus P., Eap C.B., 2016/12. Pharmacogenetics and genomics, 26 (12) pp. 547-557. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BFD29890FF60]
 
Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts.
Marie-Claire C., Crettol S., Cagnard N., Bloch V., Mouly S., Laplanche J.L., Bellivier F., Lepine J.P., Eap C., Vorspan F., 2016/02. Epigenomics, 8 (2) pp. 181-195. Peer-reviewed.
[DOI][Pmid][serval:BIB_8A903190C0C4]
Eine unerwünschte Wirkung von Methadon und Moxifloxacin
Liakoni E., Huber X., Stegert M., Crettol S., Eap CB., Liechti ME., 2016. Schweizerisches Medizin-Forum, 16 pp. 176-177. Peer-reviewed.
[URN][serval:BIB_21191F2448D1]
Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Wojtowicz A., Bibert S., Beckmann S., Mueller N.J., Binet I. et al., 2016. PloS one, 11 (10) pp. e0164443. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ADE82491851D]
2015
 
The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens.
Sakae D.Y., Marti F., Lecca S., Vorspan F., Martín-García E., Morel L.J., Henrion A., Gutiérrez-Cuesta J., Besnard A., Heck N. et al., 2015. Molecular Psychiatry, 20 (11) pp. 1448-1459. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A7353BF80F5C]
2014
Can Valproic Acid be an Inducer of Clozapine Metabolism?
Diaz F.J., Eap C.B., Ansermot N., Crettol S., Spina E., de Leon J., 2014. Pharmacopsychiatry, 47 (3) pp. 89-96. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B56EBAE8B792]
 
Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.
Crettol S., de Leon J., Hiemke C., Eap C.B., 2014. Clinical Pharmacology and Therapeutics, 95 (3) pp. 254-257. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_279EB3D167CB]
2013
 
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M., Crettol S., Oneda B., Lahyani R., Rotger M., Choong E., Lubomirov R., Csajka C., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (2) pp. 84-93. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B0FCBF667C36]
 
Cytochrom-P450-Genotypisierung: ein Instrument zur Personalisierung der medikamentösenBehandlung in der Psychiatrie
Crettol Séverine, Eap Chin Bin, 2013. Pipette : Swiss Laboratory Medicine 6 pp. 10-11.
[URN][serval:BIB_0CD1E7557591]
 
Cytochromes P450: génotypage et /ou phénotypage pour l'individualisation du traitement médicamenteux
Crettol Séverine, Eap Chin B., 2013. Pipette 1 pp. 10-11.
[serval:BIB_99F58FB6F8C6]
2012
 
Adherence to antidepressant treatment: what the doctor thinks and what the patient says.
Loayza N., Crettol S., Riquier F., Eap C.B., 2012. Pharmacopsychiatry, 45 (5) pp. 204-207. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DCE377FB63ED]
 
Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression
Jaquenoud Sirot E., Harenberg S., Vandel P., Mendonça Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. pp. 45 - A10 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
[DOI][serval:BIB_6D36408A49CA]
 
Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression.
Jaquenoud Sirot E.veline, Harenberg Sabine, Vandel Pierre, Lima Carlos .A., Perrenoud Patrick, Kemmerling Klaus, Zullino Daniele .F., Hilleret Henriette, Crettol Séverine, Jonzier-Perey Michèle et al., 2012. Journal of Clinical Psychopharmacology, 32 (5) pp. 622-629. Peer-reviewed.
[DOI][Pmid][serval:BIB_A42ABEFEA2B4]
2011
Addition of aripiprazole to the clozapine may be useful in reducing anxiety in treatment-resistant schizophrenia.
Chanachev A., Ansermot N., Crettol Wavre S., Nowotka U., Stamatopoulou M.E., Conus P., Eap C.B., 2011. Case Reports In Psychiatry, 2011 p. 846489. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_70D83905314A]
 
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
Oneda B., Crettol S., Bochud M., Besson J., Croquette-Krokar M., Hämmig R., Monnat M., Preisig M., Eap C.B., 2011. Pharmacogenomics Journal, 11 (4) pp. 258-266. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_02BE3E233F45]
2010
 
Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N., Crettol S., d'Esposito F., Tattam B., Hibbs D.E., Murray M., 2010/11. British journal of pharmacology, 161 (5) pp. 1059-1069. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5D2272749610]
 
Does Methadone Prolong QTc Intervals by Depleting Testosterone Levels?—Reply
Ansermot Nicolas, Albayrak Oezguer, Schlaepfer Juerg, Wavre Crettol Séverine, Croquette-Krokar Marina, Bourquin Michel, Deglon J.J., Faouzi M., Rey F., Scherbaum N. et al., 2010/08/09. Archives of Internal Medicine, 170 (15) p. 1407. Peer-reviewed.
[DOI][WoS][serval:BIB_C13BF53FCF4F]
 
Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval.
Ansermot N., Albayrak O., Schläpfer J., Crettol S., Croquette-Krokar M., Bourquin M., Déglon J.J., Faouzi M., Scherbaum N., Eap C.B., 2010/03/22. Archives of internal medicine, 170 (6) pp. 529-536. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2447D2DCD9A6]
 
Evidence-based medicine for pharmacogenetics
Rossier Michel F., Rebsamen Michaela, Crettol Severine, Eap Chin B., Rentsch Katharina, 2010. Pipette : Swiss Loboratory Medicine 4 pp. 13-15.
[serval:BIB_3432451F8CA0]
 
Pharmacogenetics of phase I and phase II drug metabolism.
Crettol S., Petrovic N., Murray M., 2010. Current pharmaceutical design, 16 (2) pp. 204-219. Peer-reviewed.
[WoS][Pmid][serval:BIB_331139196F75]
2009
 
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B., Crettol S., Jaquenoud Sirot E., Bochud M., Ansermot N., Eap C.B., 2009/11. Pharmacogenetics and genomics, 19 (11) pp. 877-883. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_078310C1D51D]
 
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E., Knezevic B., Morena G.P., Harenberg S., Oneda B., Crettol S., Ansermot N., Baumann P., Eap C.B., 2009/08. Journal of clinical psychopharmacology, 29 (4) pp. 319-326. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F54C2F3BEB3]
Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study.
Hallinan R., Crettol S., Agho K., Attia J., Besson J., Croquette-Krokar M., Hämmig R., Déglon J.J., Byrne A., Ray J. et al., 2009. European Journal of Clinical Pharmacology, 65 (11) pp. 1113-1120.
[URN][DOI][WoS][Pmid][serval:BIB_879A09F2BE27]
2008
 
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.
Crettol S., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., Monnat M., Déglon J.J., Preisig M., Eap C.B., 2008. Progress in Neuro-psychopharmacology and Biological Psychiatry, 32 (7) pp. 1722-1727. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5E88F9AD4B4A]
 
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S., Venetz J.P., Fontana M., Aubert J.D., Pascual M., Eap C.B., 2008. Therapeutic Drug Monitoring, 30 (6) pp. 689-699. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BC6922E390E7]
 
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Fontana Massimiliano, Aubert John-David, Ansermot Nicolas, Fathi Marc, Pascual Manuel, Eap Chin-Bin, 2008. Pharmacogenetics and Genomics, 18 (4) pp. 307-315. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B47AB7C75055]
 
No influence of ABCB1 haplotypes on methadone dosage requirement
Crettol Séverine, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Hämmig Robert, Gothuey Isabelle, Monnat Martine, Eap Chin-Bin, 2008. Clinical Pharmacology and Therapeutics, 83 (5) pp. 668-669. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CEBA2B2D973]
 
Response to "methadone-induced QTc prolongation: is it due to stereoselective block of hERG or to inappropriate QT interval correction?"
Crettol Séverine, Schlaepfer Jürg, Abriel Hugues, Eap Chin-Bin, 2008. Clinical Pharmacology and Therapeutics, 83 (5) p. 672. Peer-reviewed.
[DOI][WoS][serval:BIB_318CB91606C3]
 
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizer: evidence of a safer cardiac profile of (R)-methadone
Eap Chin Bin, Crettol Séverine, Rougier Jean-Sébastien, Schläpfer Jürg, Sintra Grilo Liliana, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Carrupt Pierre-Alain, Abriel Hugues, 2008. pp. A6 dans 5th Regensburg Symposium on Clinical Pharmacology, Pharmacopsychiatry. Peer-reviewed.
[DOI][serval:BIB_E1A09D2D578F]
2007
Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?
Crettol S., Monnat M., Eap C.B., 2007. Critical Care, 11 (1) p. 119. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4436790B32FC]
 
In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites
Crettol Séverine, Digon Patricia, Powell Golay Kerry, Brawand Marlyse, Eap Chin-Bin, 2007. Pharmacology, 80 (4) pp. 304-311. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7DD3F39D7F18]
 
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients
Uehlinger Claude, Crettol Séverine, Chassot Philippe, Brocard Murielle, Koeb Liliane, Brawand-Amey Marlyse, Eap Chin-Bin, 2007. Journal of Clinical Psychopharmacology, 27 (3) pp. 273-278. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14C9CA4BBD65]
 
Pharmacokinetic and pharmacogenetic factors influencing methadone plasma levels
Crettol Séverine, Eap Chin-Bin, 2007. Heroin Addiction and Related Clinical Problems, 9 (2) pp. 39-46. Peer-reviewed.
[serval:BIB_E8D5A9077B7E]
 
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.
Eap C.B., Crettol S., Rougier J.S., Schläpfer J., Sintra Grilo L., Déglon J.J., Besson J., Croquette-Krokar M., Carrupt P.A., Abriel H., 2007. Clinical Pharmacology and Therapeutics, 81 (5) pp. 719-728. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DBDA92B48C27]
2006
 
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S., Déglon J.J., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., Monnat M., Eap C.B., 2006. Clinical pharmacology and therapeutics, 80 (6) pp. 668-81. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9E02532BEA1]
 
Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status.
Baumann P., Barbe R., Vabre-Bogdalova A., Garran E., Crettol S., Eap C.B., 2006. Journal of clinical psychopharmacology, 26 (6) pp. 679-81. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C2275B85B7A2]
 
Epileptiform seizure following sertraline treatment in an adolescent suffering from obsessive compulsive disorder and presenting a rare pharmacogenetic status
Baumann Pierre, Barbe R., Vabre-Bogdalova A., Garran E., Crettol Séverine, Eap Chin B., 2006. Journal of Clinical Psychopharmacology, 26 (6) pp. 679-681.
[serval:BIB_904321AD6133]
 
Genetic polymorphisms of CYP3A genes affect cyclosporine a blood concentration and dose requirement in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Aubert John-David, Fontana Massimiliano, Brocard Murielle, Pascual Manuel, Eap Chin-Bin, 2006. p. 197 dans NA, Transplantation. Peer-reviewed.
[serval:BIB_1DF48FD34AEB]
 
Influence of MDR1 genetic polymorphisms on intralymphocyte concentrations of cyclosporine A in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Aubert John-David, Fontana Massimiliano, Ansermot Nicolas, Fathi Marc, Brocard Murielle, Pascual Manuel, Eap Chin-Bin, 2006. p. 197 dans NA, Transplantation. Peer-reviewed.
[serval:BIB_2593E2C77971]
 
Pharmacogenomics of opioids
Crettol Séverine, Eap Chin-Bin, 2006. dans Pharmacogenomics and proteomics : enabling the practice of personalized medicine / ed. by Steven H.Y. Wong, Mark W. Linder, Roland Valdes. - Washington, DC : AAC Press, 2006. - P. 187-198. - ISBN 1594250464, NA.
[serval:BIB_2779A49BFF28]
2005
 
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients.
Bondolfi G., Morel F., Crettol S., Rachid F., Baumann P., Eap C.B., 2005. Therapeutic drug monitoring, 27 (4) pp. 539-43. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_08E3B822BB7E]
 
Influence of CYP2B6 polymorphism on the steady-state plasma levels of the enantiomers of methadone
Crettol Séverine, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Gottuey I., Haemming R., Monnat Martine, Haottemann H., Baumann Pierre, Eap Chin-Bin, 2005. p. 121 dans NA, Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
[serval:BIB_87B68E9596B7]
 
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S., Déglon J.J., Besson J., Croquette-Krokkar M., Gothuey I., Hämmig R., Monnat M., Hüttemann H., Baumann P., Eap C.B., 2005. Clinical pharmacology and therapeutics, 78 (6) pp. 593-604. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DEE85807A54C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University